0001209191-20-049271.txt : 20200902 0001209191-20-049271.hdr.sgml : 20200902 20200902200013 ACCESSION NUMBER: 0001209191-20-049271 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200901 FILED AS OF DATE: 20200902 DATE AS OF CHANGE: 20200902 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BENZENO SHARON CENTRAL INDEX KEY: 0001780854 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 201158071 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-01 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001780854 BENZENO SHARON C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200 SEATTLE WA 98102 0 1 0 0 Chief Business Development Off Common Stock 2020-09-01 4 M 0 2604 6.55 A 2604 D Common Stock 2020-09-01 4 M 0 2604 6.55 A 5208 D Common Stock 2020-09-01 4 M 0 1563 7.27 A 6771 D Common Stock 2020-09-01 4 S 0 6471 41.28 D 300 D Common Stock 2020-09-01 4 S 0 300 41.75 D 0 D Stock Option (Right to Buy) 6.55 2020-09-01 4 M 0 2604 0.00 D 2028-02-07 Common Stock 2604 36459 D Stock Option (Right to Buy) 6.55 2020-09-01 4 M 0 2604 0.00 D 2028-10-01 Common Stock 2604 65105 D Common Stock (Right to Buy) 7.27 2020-09-01 4 M 0 1563 0.00 D 2029-02-07 Common Stock 1563 43750 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.72 to 41.70, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Sharon Benzeno by Eric Billings, Attorney in Fact 2020-09-02